Skip to main content
KimeraCHEMS
Display
  • C
  • N
  • O

Calculated reference model · not an experimental or batch-certified structure. All 16 atoms shown.

Model data & sources
  • Heavy atoms only; hydrogens are omitted from the reference display.
  • Source-defined stereochemistry is checked against the calculated coordinates; no energy-minimum, crystal or solution-structure claim is made.
  • Reference molecular species only; batch identity, purity, counterions and excipients are not certified.
Formula
C12H13NO3
Method
RDKit ETKDGv3 / MMFF94s calculated reference conformer
Batch 1 of 2
KC-ANI-02
Batch 2 of 2
KC-ANI-03
The forms on this page come off different batches, so more than one code is shipping. Each has its own certificate, and the code printed on your label is the one you have.

Aniracetam

Nootropics

Published formats

  • Dry-Fill Capsule 120ct/400mg/48g
  • Powder 50g
What is the difference between these?
Dry-Fill Capsule
Capsules filled with the weighed solid. The label gives the amount in each capsule and the number in the bottle.
Powder
Raw material as a solid. Nothing added and nothing portioned; the stated weight is what is in the container.
Each label gives the amount per unit and the total, so compare the totals rather than the container size.

Supplementary product details from the published catalog, checked 2026-10-07. These reference details do not establish current availability.

Pricing

Pricing and order placement are reserved for reviewed research accounts. Log in or submit an account application to view current product pricing.

Technical Specifications

Batch COA Database ↗
CAS Registry Number72432-10-1
Molecular FormulaC₁₂H₁₃NO₃
Molecular Weight219.24
IUPAC Designation1-(4-methoxybenzoyl)pyrrolidin-2-one
Physical FormRefer to product documentation
Storage RequirementsRefer to product documentation
Other Names72432-10-1, Draganon, Sarpul, Ampamet, Ro 13-5057, Aniracetamun, Memodrin
Capsule Concentration400mg x 120ct
Bulk Powder Quantity50g

Identity fields from the published product record, checked 2026-10-07. Reference information is not a batch identity certificate.

Research Overview

Aniracetam

Aniracetam is a synthetic racetam derivative originally developed in the 1970s and heavily documented across neurochemical, cognitive, and synaptic transmission research models. Structurally related to piracetam, Aniracetam is distinguished by its significantly higher lipophilicity, which directly influences its molecular distribution properties and cell membrane permeability in laboratory environments. It serves as a fundamental benchmark compound in comparative pharmacology and structure-activity relationship (SAR) studies targeting central nervous system mechanics.

Physical & Handling Properties

Property Specification
Solubility Profile Lipophilic; highly soluble in organic solvents (such as DMSO and ethanol); poorly soluble in aqueous environments

Mechanism of Action & Core Research Interests

In vitro and in vivo laboratory designs focus heavily on Aniracetam due to its role as a positive allosteric modulator of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors. Because it functions as an ampakine-like agent rather than a direct receptor agonist, it changes receptor kinetics without direct activation.

Scientists utilize this mechanism to evaluate:

  • Synaptic Efficiency: Observing alterations in baseline synaptic responsiveness and signal transmission integrity between neurons.

  • Long-Term Potentiation (LTP): Investigating cellular mechanisms underlying synaptic plasticity, learning pathways, and memory formation models.

  • Secondary Neuromodulation: Evaluating indirect downstream influences on dopaminergic and serotonergic signaling pathways.

  • Class Comparisons: Testing alongside related molecules like oxiracetam and pramiracetam to map out structural tolerance profiles across the broader racetam family.

Storage & Laboratory Preservation

Store at controlled room temperature. Keep tightly closed.

Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.

Related Research Compounds

Frequently Asked Questions

Why is Aniracetam classified as an ampakine-like compound in research?

Aniracetam is categorized this way because it acts as a positive allosteric modulator of AMPA-type glutamate receptors. It slows down receptor desensitization and deactivation rather than directly binding as a baseline agonist.

How does Aniracetam’s solubility affect its laboratory preparation?

Aniracetam is highly lipophilic (fat-soluble) and exhibits very poor solubility in plain water. For accurate laboratory assay preparation, it must be dissolved into compatible organic solvents like dimethyl sulfoxide (DMSO) or ethanol before being introduced to experimental buffers.

Is this compound identical to Piracetam?

No. While it shares a foundational chemical lineage, Aniracetam features an anisoyl modification at the pyrrolidinone core. This structural adjustment dramatically increases its lipophilicity and modifies its receptor binding affinity compared to first-generation racetams.

Research Use Only Disclaimer: This product is developed, manufactured, and distributed strictly as a Research Use Only (RUO) chemical compound intended exclusively for in vitro laboratory assays and academic investigation. It is not a dietary supplement, medication, or consumer drug product, and it is strictly unapproved for human or veterinary consumption. Kimera Chems explicitly prohibits its use for therapeutic, clinical, or diagnostic applications.

Certificates of Analysis

Currently shipping from batches KC-ANI-02 and KC-ANI-03. The code printed on your label says which one you have.

Kimera Chems

Compounds That Survive Scrutiny

Research use only. Not for human or veterinary use.